Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: Incidence, radiological, and clinicopathological features

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 10, 2007, Pages 3829-3835

  Suliman, S G I ^a   Gurlek, A ^a,b,c   Byrne, J V ^b   Sullivan, N ^b   Thanabalasingham, G ^a   Cudlip, S ^b   Ansorge, O ^b   Wass, John A H ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; PROTEINASE ACTIVATED RECEPTOR 1; UVOMORULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL DENSITY; CELL INFILTRATION; CEREBROSPINAL FLUID RHINORRHEA; CHEMICAL ANALYSIS; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUORRHEA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORBIDITY; NONFUNCTIONING PITUITARY ADENOMA; PATHOLOGY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; RADIOLOGY; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 35349023169     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0373     Document Type: Article

References (43)

1. Ciric I, Ragin A, Baumgartner C, Pierce D 1997 Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225-236; discussion 236-237
2. Landolt AM 1982 Cerebrospinal fluid rhinorrhea: a complication of therapy for invasive prolactinomas. Neurosurgery 11:395-401
3. Cole IE, Keene M 1980 Cerebrospinal fluid rhinorrhea in pituitary tumours. J R Soc Med 73:244-254
4. Aarabi B, Leibrock LG 1992 Neurosurgical approaches to cerebrospinal fluid rhinorrhea. Ear Nose Throat J 71:300-305
5. Obana WG, Hodes JE, Weinstein PR, Wilson CB 1990 Cerebrospinal fluid rhinorrhea in patients with untreated pituitary adenoma: report of two cases. Surg Neurol 33:336-340
6. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA 2000 CSF rhinorrhea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 52:43-49
7. Aronoff SL, Daughaday WH, Laws Jr ER 1979 Bromocriptine treatment of prolactinomas. N Engl J Med 300:1391
8. Wood R, Sandeman DD, Gawne-Cain ML, Holt RI 2002 Meningitis four years after treatment of macroprolactinoma. J R Soc Med 95:501-502
9. Barlas O, Bayindir C, Hepgul K, Can M, Kiris T, Sencer E, Unal F, Aral F 1994 Bromocriptine-induced cerebrospinal fluid fistula in patients with macroprolactinomas: report of three cases and a review of the literature. Surg Neurol 41:486-489
10. Nadesapillai S, Balcere I, Kaye AH, Tress BM, Colman PG 2004 Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon? J Clin Neurosci 11:825-828
11. Hildebrandt G, Zierski J, Christophis P, Laun A, Schatz H, Lancranjan I, Klug N 1989 Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma. Acta Neurochir (Wien) 96:107-113
12. Hanel RA, Prevedello DM, Correa A, Antoniuk A, Araujo JC 2001 Cerebrospinal fluid fistula as the presenting manifestation of pituitary adenoma: case report with a 4-year follow-up. Arq Neuropsiquiatr 59:263-265
13. Bronstein MD, Musolino NR, Benabou S, Marino Jr R 1989 Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas. Surg Neurol 32:346-349
14. Kok JG, Bartelink AK, Schulte BP, Smals A, Pieters G, Meyer E, Merx H 1985 Cerebrospinal fluid rhinorrhea during treatment with bromocriptine for prolactinoma. Neurology 35:1193-1195
15. Wilson JD, Newcombe RL, Long FL 1983 Cerebrospinal fluid rhinorrhea during treatment of pituitary tumours with bromocriptine. Acta Endocrinol (Copenh) 103:457-460
16. Cappabianca P, Lodrini S, Felisati G, Peca C, Cozzi R, Di Sarno A, Cavallo LM, Giombini S, Colao A 2001 Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. J Endocrinol Invest 24:183-187
17. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R 1998 Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4:909-914
18. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A 2005 PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313
19. Martin CB, Mahon GM, Klinger MB, Kay RJ, Symons M, Der CJ, Whitehead IP 2001 The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 20:1953-1963
20. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M 2003 Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 162:1503-1513
21. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, Harris AL 2002 Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 62:1326-1329
22. Giraudo E, Inoue M, Hanahan D 2004 An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633
23. Varney ML, Johansson SL, Singh RK 2005 Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 15:417-425
24. Condeelis J, Pollard JW 2006 Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-266
25. Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA 2000 Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85:2931-2935
26. Vleminckx K, Vakaet Jr L, Mareel M, Fiers W, van Roy F 1991 Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107-119
27. Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, Tashiro T, Horiguchi H, Wakatsuki S, Hirokawa M, Sano T 2002 Role of E-cadherin, α-, β-, and γ-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol 15:1357-1365
28. Kawamoto H, Mizoue T, Arita K, Tominaga A, Eguchi K, Kurisu K 1997 Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. J Neurooncol 34:105-109
29. Baskin DS, Wilson CB 1982 CSF rhinorrhea after bromocriptine for prolactinoma. N Engl J Med 306:178
30. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G 2003 Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325-331
31. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J 1997 Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102-2107
32. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Dano K, Nielsen BS 2006 MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4:293-302
33. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159-1162
34. Colao A, Annunziato L, Lombardi G 1998 Treatment of prolactinomas. Ann Med 30:452-459
35. Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Libe R, Faglia G, Ambrosi B 2001 A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci 45:65-69
36. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
37. Molitch ME 2005 Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52
38. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A 1994 Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314-322
39. Zornitzki T, Knobler H, Nass D, Hadani M, Shimon I 2004 Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case of prolactinoma. Horm Res 61:111-116
40. Delgrange E, Duprez T, Maiter D 2006 Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf) 64:456-462
41. Honegger JB, Psaras T, Petrick M, Beuschlein F, Reincke M 2006 Spontaneous cerebrospinal fluid rhinorrhea in untreated macroprolactinoma - an indication for primary surgical therapy. Zentralbl Neurochir 67:149-154
42. Okuyama T, Sato O, Daibo M, Niwa J 1984 [Cessation of cerebrospinal fluid rhinorrhea by bromocriptine treatment of a patient with invasive prolactinoma]. No Shinkei Geka 12:319-323
43. Netea-Maier RT, van Lindert EJ, Timmers H, Schakenraad EL, Grotenhuis JA, Hermus AR 2006 Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas. J Endocrinol Invest 29:1001-1005